clear of art of.

10/510,680 Yong Chu, 9-20-2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptaylc1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS 4	MAY 10	CA/CAplus enhanced with 1900-1906 U.S. patent records
NEWS 5	MAY 11	KOREAPAT updates resume
NEWS 6	MAY 19	Derwent World Patents Index to be reloaded and enhanced
NEWS 7	MAY 30	IPC 8 Rolled-up Core codes added to CA/CAplus and USPATFULL/USPAT2
NEWS 8	MAY 30	The F-Term thesaurus is now available in CA/CAplus
NEWS 9	JUN 02	The first reclassification of IPC codes now complete in INPADOC
NEWS 10	JUN 26	TULSA/TULSA2 reloaded and enhanced with new search and and display fields
NEWS 11	JUN 28	Price changes in full-text patent databases EPFULL and PCTFULL
NEWS 12	JUl 11	CHEMSAFE reloaded and enhanced
NEWS 13	JUl 14	FSTA enhanced with Japanese patents
NEWS 14	JUl 19	Coverage of Research Disclosure reinstated in DWPI
NEWS 15	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS 16	AUG 28	ADISCTI Reloaded and Enhanced
NEWS 17	AUG 30	CA(SM)/CAplus(SM) Austrian patent law changes
NEWS 18	SEP 11	CA/CAplus enhanced with more pre-1907 records

NEWS EXPRESS JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:30:45 ON 20 SEP 2006

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

CM 2

CRN 71-47-6
CMF C H O2



=> file reg
COST IN U.S. DOLLARS — SINCE FILE ENTRY: 6.03 — TOTAL SESSION: 521.86

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) — SINCE FILE ENTRY: -0.75 — TOTAL SESSION: -2.25

FILE 'REGISTRY' ENTERED AT 15:39:42 ON 20 SEP 2006

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 SEP 2006 HIGHEST RN 907944-91-6
DICTIONARY FILE UPDATES: 19 SEP 2006 HIGHEST RN 907944-91-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

Effective September 24, 2006, Concord 3D coordinates will no longer be available. Please contact CAS Customer Care (http://www.cas.org/supp.html) if you have a need for 3D coordinates.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Documents and Settings\ychu\Desktop\Case\10510680\10510680F.str

L16 STRUCTURE UPLOADED

=> d
L16 HAS NO ANSWERS
L16 STR



G1 O,S

Structure attributes must be viewed using STN Express query preparation.

=> s l16
SAMPLE SEARCH INITIATED 15:40:18 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 1005 TO ITERATE

100.0% PROCESSED 1005 ITERATIONS 3 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 18199 TO 22001
PROJECTED ANSWERS: 3 TO 163

L17 3 SEA SSS SAM L16

=> s l16 full
FULL SEARCH INITIATED 15:40:26 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 19091 TO ITERATE

100.0% PROCESSED 19091 ITERATIONS 55 ANSWERS
SEARCH TIME: 00.00.01

L18 55 SEA SSS FUL L16

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	167.38	689.24

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-2.25

FILE 'CAPLUS' ENTERED AT 15:40:37 ON 20 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.



I

AB Title muscarinic receptor antagonists I (X = O, NH, etc.; R1 = OH, etc.; R2 = H, halo, alkyl; R3 = H, OH, etc.; R4, R5, R6 = H, alkyl; ; Z = CH2, SO2, carbonyl; W = alkylene, etc.; R = alkyl, aryl, etc.), useful for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors, are prepd. The affinity of these compds. for M2 and M3 muscarinic receptor subtype was tested. For example, (3S)-1-benzylpyrrolidin-3-yl cyclopentyl(hydroxy)phenylacetate was prepd. and had pKi = 6.13/7.17 for the M2 and M3 receptor subtype resp.

IT 719278-65-6P 719278-66-7P 719278-72-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 1-substituted-3-pyrrolidine derivs. as muscarinic receptor antagonists)

RN 719278-65-6 CAPLUS
CN Benzeneacetic acid, .alpha.-cyclopentyl-.alpha.-hydroxy-, (3S)-1-[[4-(trifluoromethyl)phenyl]sulfonyl]-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 719278-66-7 CAPLUS
CN Benzeneacetic acid, .alpha.-cyclopentyl-.alpha.-hydroxy-, (3S)-1-[(4-nitrophenyl)sulfonyl]-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 719278-72-5 CAPLUS
CN Benzeneacetic acid, .alpha.-cyclopentyl-.alpha.-hydroxy-, (3S)-1-[(4-bromophenyl)sulfonyl]-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN Current application

ACCESSION NUMBER: 2003:837081 CAPLUS
DOCUMENT NUMBER: 139:337885
TITLE: Preparation of acyloxypyrrolidinium salts as M3 muscarinic antagonists
INVENTOR(S): Prat Quinones, Maria; Fernandez Forner, Maria Dolors
PATENT ASSIGNEE(S): Almirall Prodesfarma S.A., Spain
SOURCE: PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003087094	A2	20031023	WO 2003-EP3786	20030411
WO 2003087094	A3	20040318		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
ES 2206021	A1	20040501	ES 2002-889	20020416
ES 2206021	B1	20050801		
CA 2482536	AA	20031023	CA 2003-2482536	20030411
AU 2003233967	A1	20031027	AU 2003-233967	20030411
EP 1497284	A2	20050119	EP 2003-727294	20030411
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003009167	A	20050125	BR 2003-9167	20030411
CN 1662527	A	20050831	CN 2003-813892	20030411
ZA 2004008335	A	20051102	ZA 2004-8335	20041014
NO 2004004826	A	20050114	NO 2004-4826	20041105
US 2005282875	A1	20051222	US 2005-510680	20050720

PRIORITY APPLN. INFO.: ES 2002-889 A 20020416
WO 2003-EP3786 W 20030411

OTHER SOURCE(S): MARPAT 139:337885
GI



X⁻ I





II

AB Pyrrolidinium derivs. I [R = (un)substituted Ph, naphthalenyl, 5,6,7,8-tetrahydronaphthalenyl, benzo[1,3]dioxolyl, biphenyl, heteroarom.; R1 = alkyl; R2 = CR3R4R5, Q; R3 = 2-furyl, 3-furyl, 2-thienyl, 3-thienyl; R4 = 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, cycloalkyl; R5 = H, OH, Me, CH2OH; Q1 = CH2, CH2CH2, O, OCH2, S, SCH2, CH:CH; A = (un)substituted CH:CH, CH2, CO, O, S, S(O), SO2, NH; m = 0-8; n = 0-4] were prepd. for use in therapy as antagonists of M3 muscarinic receptors (no data). Thus, (3R)-3-pyrrolidinol was treated with 2-(3-bromopropyl)thiophene to give (3R)-1-(3-thien-2-ylpropyl)pyrrolidinol which was treated with Me 2-hydroxy-2,2-dithen-2-ylacetate and quaternized to give the pyrrolidinium salt II.

IT 616865-64-6P 616865-65-7P
RL: PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of acyloxypyrrolidinium salts as M3 muscarinic antagonists)

RN 616865-64-6 CAPLUS

CN Pyrrolidinium, 3-[(hydroxydi-2-thienylacetyl)oxy]-1-methyl-1-(3-phenoxypropyl)-, bromide, (1S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Br⁻

RN 616865-65-7 CAPLUS
CN Pyrrolidinium, 3-[(hydroxydi-2-thienylacetyl)oxy]-1-methyl-1-(3-phenoxypropyl)-, bromide, (1R,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Br^-

IT 616866-05-8P 616866-06-9P 616866-07-0P
616866-08-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of acyloxypyrrolidinium salts as M3 muscarinic antagonists)

RN 616866-05-8 CAPLUS
CN 2-Thiopheneacetic acid, .alpha.-hydroxy-.alpha.-2-thienyl-, (3R)-1-(2-phenoxyethyl)-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616866-06-9 CAPLUS
CN 2-Thiopheneacetic acid, .alpha.-hydroxy-.alpha.-2-thienyl-, (3R)-1-(2-phenoxyethyl)-3-pyrrolidinyl ester, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 616866-05-8
CMF C22 H23 N O4 S2

Absolute stereochemistry.



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 616866-07-0 CAPLUS
CN 2-Thiopheneacetic acid, .alpha.-hydroxy-.alpha.-2-thienyl-, (3R)-1-(3-phenoxypropyl)-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616866-08-1 CAPLUS
CN 2-Thiopheneacetic acid, .alpha.-hydroxy-.alpha.-2-thienyl-, (3R)-1-(3-phenoxypropyl)-3-pyrrolidinyl ester, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 616866-07-0
CMF C23 H25 N O4 S2

Absolute stereochemistry.



CM 2

CRN 144-62-7
CMF C2 H2 O4



IT 616865-58-8P 616865-59-9P 616865-60-2P
616865-62-4P 616865-63-5P 616865-76-0P
616865-77-1P 616865-78-2P 616865-86-2P

616865-87-3P 616865-88-4P 616865-89-5P
616865-90-8P 616865-91-9P 616865-92-0P
616865-93-1P 616865-94-2P 616865-95-3P
616865-96-4P 616866-00-3P 616866-02-5P
616866-04-7P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of acyloxypyrrolidinium salts as M3 muscarinic antagonists)

RN 616865-58-8 CAPLUS
CN Pyrrolidinium, 3-[(hydroxydi-2-thienylacetyl)oxy]-1-methyl-1-(2-phenoxyethyl)-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Br^-

RN 616865-59-9 CAPLUS
CN Pyrrolidinium, 3-[(hydroxydi-2-thienylacetyl)oxy]-1-methyl-1-(2-phenoxyethyl)-, bromide, (1R,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Br^-

RN 616865-60-2 CAPLUS
CN Pyrrolidinium, 3-[(hydroxydi-2-thienylacetyl)oxy]-1-methyl-1-(2-phenoxyethyl)-, bromide, (1S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Br^-

RN 616865-62-4 CAPLUS
CN Pyrrolidinium, 3-[(hydroxydi-2-thienylacetyl)oxy]-1-methyl-1-(3-phenoxypropyl)-, bromide (9CI) (CA INDEX NAME)



● Br^-

RN 616865-63-5 CAPLUS
CN Pyrrolidinium, 3-[(hydroxydi-2-thienylacetyl)oxy]-1-methyl-1-(3-phenoxypropyl)-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Br^-

RN 616865-76-0 CAPLUS
CN Pyrrolidinium, 3-[(cyclohexyl-2-furanylhydroxyacetyl)oxy]-1-methyl-1-[2-(phenylmethoxy)ethyl]-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Br^-

RN 616865-77-1 CAPLUS
CN Pyrrolidinium, 3-[[(2R)-cyclopentylhydroxyphenylacetyl]oxy]-1-methyl-1-[2-(phenylmethoxy)ethyl]-, bromide, (1R,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Br^-

RN 616865-78-2 CAPLUS
CN Pyrrolidinium, 3-[[(2R)-cyclopentylhydroxyphenylacetyl]oxy]-1-methyl-1-[2-(phenylmethoxy)ethyl]-, bromide, (1S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Br^-

RN 616865-86-2 CAPLUS
CN Pyrrolidinium, 1-[3-(2-benzothiazolyloxy)propyl]-3-[[(2R)-cyclohexyl-2-furanylhydroxyacetyl]oxy]-1-methyl-, chloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Cl⁻

RN 616865-87-3 CAPLUS
CN Pyrrolidinium, 1-[3-(2-benzothiazolyloxy)propyl]-3-[[(2S)-cyclohexyl-2-furanylhydroxyacetyl]oxy]-1-methyl-, chloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Cl⁻

RN 616865-88-4 CAPLUS
CN Pyrrolidinium, 1-[3-(2-benzothiazolyloxy)propyl]-3-[(cyclohexyl-2-furanylhydroxyacetyl)oxy]-1-methyl-, chloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Cl⁻

RN 616865-89-5 CAPLUS
CN Pyrrolidinium, 3-[[(2R)-cyclohexyl-2-furanylhydroxyacetyl]oxy]-1-ethyl-1-

[3-(phenylthio)propyl]-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Br^-

RN 616865-90-8 CAPLUS
CN Pyrrolidinium, 3-[[(2S)-cyclohexyl-2-furanylhydroxyacetyl]oxy]-1-ethyl-1-[3-(phenylthio)propyl]-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Br^-

RN 616865-91-9 CAPLUS
CN Pyrrolidinium, 3-[[(2R)-cyclopentylhydroxyphenylacetyl]oxy]-1-methyl-1-[3-(phenylthio)propyl]-, bromide, (1R,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Br^-

RN 616865-92-0 CAPLUS
CN Pyrrolidinium, 3-[[(2R)-cyclopentylhydroxyphenylacetyl]oxy]-1-methyl-1-[3-(phenylthio)propyl]-, bromide, (1S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Br^-

RN 616865-93-1 CAPLUS
CN Pyrrolidinium, 3-[[(2R)-cyclopentylhydroxyphenylacetyl]oxy]-1-methyl-1-[3-[(5,6,7,8-tetrahydro-2-naphthalenyl)oxy]propyl]-, bromide, (1S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Br^-

RN 616865-94-2 CAPLUS
CN Pyrrolidinium, 3-[[(2R)-cyclopentylhydroxyphenylacetyl]oxy]-1-methyl-1-[3-[(5,6,7,8-tetrahydro-2-naphthalenyl)oxy]propyl]-, bromide, (1R,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Br^-

RN 616865-95-3 CAPLUS
CN Pyrrolidinium, 3-[[(2R)-cyclopentylhydroxyphenylacetyl]oxy]-1-[3-(4-methoxyphenoxy)propyl]-1-methyl-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Br^-

RN 616865-96-4 CAPLUS
CN Pyrrolidinium, 3-[[(2R)-cyclopentylhydroxyphenylacetyl]oxy]-1-[3-(4-methoxyphenoxy)propyl]-1-methyl-, bromide, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Br^-

RN 616866-00-3 CAPLUS
CN Pyrrolidinium, 3-[(hydroxydi-2-thienylacetyl)oxy]-1-[3-(3-hydroxyphenoxy)propyl]-1-methyl-, (3S)-, formate (9CI) (CA INDEX NAME)

CM 1

CRN 616865-99-7
CMF C24 H28 N O5 S2

Absolute stereochemistry.



CM 2

CRN 71-47-6
CMF C H O2

RN 616866-02-5 CAPLUS
CN Pyrrolidinium, 1-[3-(3-cyanophenoxy)propyl]-3-[(cyclohexyl-2-furanylhydroxyacetyl)oxy]-1-methyl-, (3R)-, formate (9CI) (CA INDEX NAME)

CM 1

CRN 616866-01-4
CMF C27 H35 N2 O5

Absolute stereochemistry.



CM 2

CRN 71-47-6
CMF C H O2

RN 616866-04-7 CAPLUS
CN Pyrrolidinium, 3-[(cyclohexyl-2-furanylhydroxyacetyl)oxy]-1-methyl-1-[3-(1-naphthalenyloxy)propyl]-, (3R)-, formate (9CI) (CA INDEX NAME)

CM 1

CRN 616866-03-6
CMF C30 H38 N O5

Absolute stereochemistry.



CM 2

CRN 71-47-6
CMF C H O2



databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 Sep 2006 VOL 145 ISS 13
FILE LAST UPDATED: 19 Sep 2006 (20060919/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l18
L19 2 L18

=> d ibib abs hitstr tot

L19 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:546475 CAPLUS
DOCUMENT NUMBER: 141:106362
TITLE: Preparation of 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
INVENTOR(S): Mehta, Anita; Gupta, Jang Bahadur; Sarma, Pakala Kumara Savithru
PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India
SOURCE: PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

102(e) overcame by Certified translation

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004056767	A1	20040708	WO 2002-IB5590	20021223
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002347552	A1	20040714	AU 2002-347552	20021223
EP 1583741	A1	20051012	EP 2002-783480	20021223
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
US 2006194862	A1	20060831	US 2006-540245	20060207
PRIORITY APPLN. INFO.:			WO 2002-IB5590 A	20021223

OTHER SOURCE(S): CASREACT 141:106362; MARPAT 141:106362
GI